Kaleido Biosciences, Inc. Common Stock
KLDO
KLDO was delisted on the 14th of April, 2022.
71 hedge funds and large institutions have $278M invested in Kaleido Biosciences, Inc. Common Stock in 2021 Q1 according to their latest regulatory filings, with 18 funds opening new positions, 22 increasing their positions, 15 reducing their positions, and 7 closing their positions.
157% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 7
118% more call options, than puts
Call options by funds: $410K | Put options by funds: $188K
47% more repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 15
16% more funds holding
Funds holding: 61 → 71 (+10)
2% more capital invested
Capital invested by funds: $273M → $278M (+$5.3M)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$29.2M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$3.66M |
| 3 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$3.54M |
| 4 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
+$2.37M |
| 5 |
FP
Flagship Pioneering
Cambridge,
Massachusetts
|
+$2.34M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$324K |
| 2 |
SFI
Susquehanna Fundamental Investments
Bala Cynwyd,
Pennsylvania
|
-$222K |
| 3 |
Wells Fargo
San Francisco,
California
|
-$133K |
| 4 |
PPA
Parametric Portfolio Associates
Seattle,
Washington
|
-$95K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$40.9K |
KLDO Hedge Fund Activity: Q1 2021 in Review
71 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Kaleido Biosciences, Inc. Common Stock (KLDO) for Q1 2021, worth a combined $278M — up 1.9% from $273M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new KLDO positions and 7 closed out — a net gain of 11 holders — while 22 added to existing stakes and 15 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $29.2M. The largest seller was Millennium Management, cutting an estimated $324K.
- 71 institutional investors held Kaleido Biosciences, Inc. Common Stock (KLDO) as of Q1 2021, up from 61 in Q4 2020.
- Funds reported $278M of Kaleido Biosciences, Inc. Common Stock stock for Q1 2021, up 1.9% quarter-over-quarter.
- 18 funds opened new Kaleido Biosciences, Inc. Common Stock positions in Q1 2021 and 7 closed out, a net change of +11 holders.
- The largest Kaleido Biosciences, Inc. Common Stock buyer in Q1 2021 was Fidelity Investments, an estimated $29.2M added.
- The largest Kaleido Biosciences, Inc. Common Stock seller in Q1 2021 was Millennium Management, an estimated $324K sold.
Based on aggregated 13F filings for Q1 2021.